Lung Cancer Alliance Awarded Innovation Impact Award
November 5, 2013-- Lung Cancer Alliance has been named one of two recipients of a new Innovation Impact Award by Celgene Corporation for the “National Framework for Excellence in Lung Cancer Screening and Continuum of Care” initiative.
Inaugurated this year, the Celgene Corporation Innovation Impact Awards program recognizes effective, innovative and successful initiatives of U.S.-based not-for-profit organizations addressing the needs of patients, caregivers and healthcare providers in today’s challenging healthcare environment in one of two therapeutic areas: hematology or oncology. Each award winner receives a $100,000 cash grant and is invited to participate in an Innovation Experience workshop.
“We are delighted to announce The Aplastic Anemia & MDS International Foundation and Lung Cancer Alliance as the recipients of our first annual Innovation Impact Awards,” said Joel W. Beetsch, PhD, Vice President of Patient Advocacy at Celgene. “Innovation is at the core of everything we do at Celgene. The Innovation Impact Awards not only recognize the significant contributions of patient and professional organizations to patient treatment and care, but also broaden the impact of the award-winning programs by helping sustain, expand, and replicate those innovative initiatives.”
The submissions for this year’s Innovation Impact Awards represented a wide range of approaches to support the hematology and oncology communities. Lung Cancer Alliance and The Aplastic Anemia & MDS International Foundation programs included a high level of innovation, strong vision, and plans to improve patient treatment, care, and survivorship.
“We are absolutely honored and thrilled to receive this prestigious award,” said Laurie Fenton Ambrose, Lung Cancer Alliance President and CEO. “We thank Celgene and the award committee for acknowledging the lifesaving impact of our National Framework of Excellence for Lung Cancer Screening and Continuum of Care. This means so much to our staff, the more than 120 screening centers of excellence following the Framework and most importantly, for those individuals diagnosed with or at risk for lung cancer. This is a proud moment and renews our commitment to saving lives through helping the community, advancing screening and accelerating lung cancer research."
LCA’s National Framework of Lung Screening Excellence and Continuum of Care launched in February 2012 to provide guidance for both consumers at risk as well as medical centers offering care. LCA convened thought leaders from all fields related to lung cancer to devise the National Framework, guiding principles of responsible screening and care, which has been adopted by over 120 medical centers nationwide and endorsed by numerous professional societies.
For more information on the Innovation Impact Award click here.
About the Aplastic Anemia & MDS International Foundation
The Aplastic Anemia & MDS International Foundation is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.
About Celgene Corporation
Celgene Corporation is headquartered in Summit, New Jersey, and is an integrated global pharmaceutical company primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information visit www.celgene.com. Learn more information about the awards.